If the patient cannot tolerate the 2.4mg dose, then decrease the dose to 1.7mg for 4 weeks
You will not get surprised by a bill increase when your provider recommends moving from 5 mg to 10 mg
Gentle stretching, low-impact exercises, and tailored routines can ease stiffness and help keep your joints strong and flexible
Key Findings: Large human studies across multiple countries have not found increased thyroid cancer rates in GLP-1 users The FDA warning applies to medullary thyroid carcinoma (MTC)only 3-4% of all thyroid cancers The warning exists because rodents developed C-cell tumors, but humans and rodents differ biologically Some studies show associations, but these are explained by detection bias (more monitoring = finding pre-existing nodules) The Clayman Thyroid Center (2,000+ thyroid cancer patients/year) has not seen an MTC pattern linked to GLP-1 use (or for that matter any other thyroid malignancy) Clinical Recommendations: Patients with MTC history or MEN2 should not take GLP-1 receptor agonists Patients with common thyroid cancers (papillary, follicular, Hrthle cell) should not assume GLP-1 caused them or will have an effect upon them Decisions should be individualized, weighing metabolic benefits against theoretical concerns GLP-1 therapy does not require additional thyroid monitoring Quick Reference for Clinicians Understanding the Question What Medications Are We Discussing
Eligibility for Apple Health for Children: Free or low-cost coverage is available Children of public employees with access to health insurance coverage under the PEBB or SEBB programs are not eligible for Apple Health for Kids with premiums Low-cost coverage (Apple Health with premiums) is only available to children who are uninsured
All five medications share common allegations that their manufacturers knew or should have known about the risks of gastroparesis, intestinal obstruction, and other severe gastrointestinal injuries, yet failed to provide adequate warnings to patients and physicians
